1344P The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on second-line or further line therapy: Real world data from the German CRISP registry

M Falk,A Stenzinger,M Tiemann,P Christopoulos,M Thomas,J Roeper,F Griesinger,L Heukamp

doi:10.1016/j.annonc.2020.08.1658

1344P The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on second-line or further line therapy: Real world data from the German CRISP registry

M Falk, A Stenzinger + Show 6 more

Open Access

https://doi.org/10.1016/j.annonc.2020.08.1658

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2020
License type: elsevier-specific: oa user license

Affiliation: Pathologie Hamburg-West, University Hospital Heidelberg, Heidelberg University, Pius Hospital Oldenburg, Carl von Ossietzky University of Oldenburg

#3rd Generation TKI #Real World Data + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

1344P The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on second-line or further line therapy: Real world data from the German CRISP registry

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.